Retatrutide 10mg

Retatrutide 10mg | Triple Agonist (GLP-1/GIP/Glucagon) | ≥99% Purity (HPLC)

Retatrutide (LY3437943) is a synthetic 39-amino-acid peptide engineered as a potent triple receptor agonist targeting glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors. This multi-pathway molecule is extensively investigated for its synergistic effects on metabolic regulation, energy balance, and body composition in preclinical and clinical models.

Research highlights Retatrutide’s potential to:

• Induce substantial and sustained body weight reduction
• Improve glycemic control and insulin sensitivity
• Enhance energy expenditure and fat oxidation
• Suppress appetite and regulate food intake
• Promote favorable changes in cardiometabolic markers (e.g., lipids, liver enzymes)
• Support liver fat reduction in models of metabolic dysfunction

As a first-in-class triple agonist, Retatrutide is of major interest in obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH/MASH) research due to its superior efficacy profile compared to single- or dual-agonist compounds.

For Research Use Only. Not for human consumption, diagnostic, therapeutic, or veterinary purposes. Strictly intended for in vitro laboratory research by qualified professionals.

Specifications:

• Sequence: Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂ (sodium salt form)
• Molecular Formula: C₂₂₃H₃₄₃F₃N₆₀O₇₀ (approx.; trifluoroacetate salt)
• Molecular Weight: ≈4731 Da
• Appearance: White lyophilized powder
• Purity: ≥99% (HPLC)
• Solubility: Water-soluble
• Storage: Lyophilized at -20°C; reconstituted at 2–8°C short-term. Protect from light and moisture.

Common Research Areas: Obesity mechanisms • Metabolic syndrome • Type 2 diabetes • Non-alcoholic fatty liver disease (NAFLD/NASH) • Incretin/glucagon signaling • Weight management pathways • Energy homeostasis